Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?

BILICI A., USTAALIOGLU B. B. O. , ERCAN S., ORCUN A., SEKER M., Salepçi T., ...More

CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.68, no.2, pp.309-316, 2011 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 68 Issue: 2
  • Publication Date: 2011
  • Doi Number: 10.1007/s00280-010-1480-0
  • Title of Journal : CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • Page Numbers: pp.309-316

Abstract

M30 and M65 are different circulating fragments of cytokeratin 18. They release during apoptotic cell death, so it is believed that they reflect cell death of epithelial tumors. The aim of this study was to determine the prognostic value of plasma M30 and M65 levels in predicting of survival for patients with advanced gastric cancer compare with healthy controls.